CIBC Asset Management Inc grew its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,005 shares of the financial services provider's stock after acquiring an additional 3,421 shares during the period. CIBC Asset Management Inc's holdings in CME Group were worth $24,935,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in CME. Wealth Enhancement Advisory Services LLC grew its holdings in CME Group by 21.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider's stock worth $9,477,000 after acquiring an additional 8,443 shares during the period. Cetera Investment Advisers raised its position in shares of CME Group by 429.1% during the first quarter. Cetera Investment Advisers now owns 47,521 shares of the financial services provider's stock worth $10,231,000 after purchasing an additional 38,540 shares during the period. Brookstone Capital Management lifted its stake in CME Group by 12.2% during the 2nd quarter. Brookstone Capital Management now owns 30,555 shares of the financial services provider's stock valued at $6,156,000 after acquiring an additional 3,325 shares in the last quarter. Epoch Investment Partners Inc. grew its stake in CME Group by 4.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 99,947 shares of the financial services provider's stock valued at $21,518,000 after purchasing an additional 4,454 shares during the period. Finally, Mather Group LLC. raised its stake in shares of CME Group by 197.2% during the 2nd quarter. Mather Group LLC. now owns 6,066 shares of the financial services provider's stock worth $1,306,000 after purchasing an additional 4,025 shares during the period. Institutional investors own 87.75% of the company's stock.
Insider Activity
In related news, insider Timothy Francis Mccourt sold 1,374 shares of the company's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $227.12, for a total value of $312,062.88. Following the sale, the insider now owns 7,275 shares in the company, valued at $1,652,298. This represents a 15.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy S. Bitsberger sold 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $226.96, for a total value of $226,960.00. Following the completion of the sale, the director now owns 10,589 shares in the company, valued at $2,403,279.44. The trade was a 8.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,621 shares of company stock worth $3,441,063. Corporate insiders own 0.30% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Barclays lifted their price target on shares of CME Group from $219.00 to $231.00 and gave the stock an "equal weight" rating in a report on Thursday, October 24th. Royal Bank of Canada reissued a "sector perform" rating and set a $235.00 price objective on shares of CME Group in a report on Thursday, October 24th. Bank of America raised their price target on shares of CME Group from $177.00 to $180.00 and gave the company an "underperform" rating in a report on Thursday, October 3rd. JPMorgan Chase & Co. raised their price target on CME Group from $187.00 to $191.00 and gave the company an "underweight" rating in a report on Thursday, July 25th. Finally, Oppenheimer lifted their price objective on shares of CME Group from $245.00 to $258.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $224.47.
Read Our Latest Report on CME Group
CME Group Price Performance
NASDAQ CME traded up $1.86 on Friday, reaching $225.28. The company had a trading volume of 2,125,179 shares, compared to its average volume of 1,914,469. The stock has a market capitalization of $81.12 billion, a PE ratio of 23.69, a price-to-earnings-growth ratio of 5.26 and a beta of 0.55. CME Group Inc. has a 12 month low of $190.70 and a 12 month high of $230.36. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.09. The firm's 50 day moving average price is $222.62 and its 200 day moving average price is $210.37.
CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.03. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the firm posted $2.25 EPS. CME Group's quarterly revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts predict that CME Group Inc. will post 10.23 earnings per share for the current year.
CME Group Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Monday, December 9th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.60 annualized dividend and a dividend yield of 2.04%. CME Group's payout ratio is currently 48.37%.
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Recommended Stories
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.